Opinion
Video
Author(s):
Panelists discuss how lorlatinib’s unique adverse event (AE) profile, including cognitive effects, hypercholesterolemia, and peripheral neuropathy, impacts treatment selection and patient management.
Lorlatinib’s Unique Adverse Event Profile
Key Themes:
Notable Insights:
Dr Lovly outlined best practices for monitoring and managing lorlatinib-induced hypercholesterolemia
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity